UPDATE 2-Novo plans larger study after encouraging semaglutide results

COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk'sexperimental injectable diabetes drug semaglutide reduced
cardiovascular risk by 26 percent, according to results released
on Friday, paving the way...